Obesity
Commentary
The ‘triple-G’ agonist for obesity management: Five things to know
Results from a phase 2 trial published in June 2023 showed a weight loss of 24%...
Conference Coverage
Tirzepatide superior to semaglutide for A1c control, weight loss
“Although the efficacy of the high tirzepatide dose might make it a favorable choice, its real-world application can be affected on an individual’...
News
Waist-hip ratio a stronger mortality predictor than BMI
“Current World Health Organization recommendations for optimal BMI range are inaccurate across individuals with various body compositions and...
News
‘New dawn’ for aldosterone as drug target in hypertension?
The medication lowered systolic blood pressure significantly more than placebo, with the greatest effects seen in adults with obesity.
News
Obesity-related cardiovascular disease deaths surging
“There is need for dedicated health strategies aimed at individual communities to better understand and tackle the social determinants of obesity...
Conference Coverage
More weight loss linked with more benefit in STEP-HFpEF
“The outcomes we’ve already seen in STEP-HFpEF were largely symptomatic, which are extraordinarily important, but there may be a completely...
Conference Coverage
Wegovy scores HFpEF benefits in people with obesity
The results “indicate that treatment with semaglutide is a valuable therapeutic approach in the management of patients with HFpEF and obesity.”
Commentary
It’s not ‘reckless’ to consider Ozempic
We are not giving a dangerous treatment (e.g., fen-phen) that increases cardiovascular risk – quite the contrary, in fact.
News
Artificial sweeteners no help for weight loss: Review
An updated review of the leading scientific evidence on artificial sweeteners suggests that far from positively affecting our health, they have “...
News
Certain genes predict abdominal fat regain after weight loss
“These findings are the first of their kind and provide new insights into the mechanisms of weight regain.”